2 years ago

uMed Raises £9.8 Million to Expand Clinical Trial Platform in North America

  • uMed, a UK-based health tech company providing a clinical trial and research platform, has secured £9.8 million in funding

  • The company plans to use the investment to expand its user base in North America, aiming to reach over 10 million patients by the end of the year

  • The funding round was led by Delin Ventures, with participation from AlbionVC, Playfair Capital, and 11.2 Capital

  • uMed's platform automates patient cohort discovery and facilitates patient communications during clinical trials and research

  • The company is currently focused on interstitial lung diseases, cardio-metabolic, and lung disease cohorts.

      • ProblemHealthcare

      "Recruiting and managing patients for clinical trials is a slow, expensive, and inefficient process."

      Solution

      "uMed provides a platform that automates patient recruitment and communication for clinical trials, making it faster, cheaper, and more efficient for healthcare providers to conduct research."

      Covered on